Fayet G, Amphoux-Fazekas T, Aouani A, Hovsépian S
Laboratoire de Biochimie Médicale et U 38 INSERM, Faculté de Médecine, Marseille, France.
Mol Cell Endocrinol. 1996 Mar 1;117(1):111-6. doi: 10.1016/0303-7207(95)03732-2.
Hexamethylenebisacetamide (HMBA) provokes in murine erythroleukemia cells (MELC) a commitment to terminal differentiation leading to the activation of the expression of hemoglobin. HMBA has been tested also in other cells from colon cancer, melanoma or lung cancer. However it has not yet been tested in the thyroid. We demonstrate in this paper that HMBA in kinetics and concentration-response experiments increases the proliferation of human thyroid cells isolated from Graves'-Basedow patients. It also acts like a growth factor for ovine and porcine thyroid cells, respectively, from the OVNIS line and the ATHOS line. This molecule which is a differentiating factor in the MELC system and a growth factor in human thyroid cell cultures represents a potential to get human thyroid cell lines expressing specialized functions.
